DK2217329T3 - Anvendelse af navlestrengsblod i behandlingen af komplikationer i forbindelse med præterm fødsel - Google Patents

Anvendelse af navlestrengsblod i behandlingen af komplikationer i forbindelse med præterm fødsel Download PDF

Info

Publication number
DK2217329T3
DK2217329T3 DK08847846.6T DK08847846T DK2217329T3 DK 2217329 T3 DK2217329 T3 DK 2217329T3 DK 08847846 T DK08847846 T DK 08847846T DK 2217329 T3 DK2217329 T3 DK 2217329T3
Authority
DK
Denmark
Prior art keywords
cord blood
umbilical cord
placenta
cells
stem cells
Prior art date
Application number
DK08847846.6T
Other languages
English (en)
Inventor
Kristine Erikson Johnson
Robert J Hariri
Mohammad A Heidaran
Original Assignee
Anthrogenesis Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anthrogenesis Corp filed Critical Anthrogenesis Corp
Application granted granted Critical
Publication of DK2217329T3 publication Critical patent/DK2217329T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48Reproductive organs
    • A61K35/51Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135Compounds containing heavy metals
    • A61K31/714Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/26Iron; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/18Erythrocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48Reproductive organs
    • A61K35/50Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1816Erythropoietin [EPO]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355Tocopherols, e.g. vitamin E
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415Pyridoxine, i.e. Vitamin B6
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525Isoalloxazines, e.g. riboflavins, vitamin B2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)

Claims (27)

  1. I
    1. Navlestrengsblod omfattende placentastamceller til anvendelse i en fremgangsmåde til behandling af en lidelse eller tilstand i et præmaturt spædbarn, 5 hvor nævnte lidelse eller tilstand er forårsaget af eller associeret med ufuldstændig udvikling af hjernen, hvor nævnte placentastamceller omfatter celler der er CD34-, CD73+ , CD1 05+ , og CD200+ .
  2. 2. Navlestrengsblodet til anvendelse ifølge krav 1, yderligere omfattende et 10 blodadditiv, hvor nævnte blodadditiv er erythropoietin, et jernsupplement, et vitamin, eller røde blodlegemer fra en kilde anden end navlestrengsblod.
  3. 3. Navlestrengsblodet til anvendelse ifølge krav 2, hvor nævnte blodadditiv er erythropoietin. 15
  4. 4. Navlestrengsblodet til anvendelse ifølge krav 3, hvor nævnte erythropoietin er rekombinant erythropoietin genetisk modificeret til at øge serum-halveringstiden sammenlignet med nativ erythropoietin.
  5. 5. Navlestrengsblodet til anvendelse ifølge krav 2, hvor nævnte blodadditiv er et vitamin.
  6. 6. Navlestrengsblodet til anvendelse ifølge krav 5, hvor nævnte vitamin er riboflavin (vitamin B2), pyridoxin (vitamin B6), folinsyre, vitamin B12, eller 25 vitamin E.
  7. 7. Navlestrengsblodet til anvendelse ifølge krav 2, hvor blodadditivet er et jernsupplement.
  8. 8. Navlestrengsblodet til anvendelse ifølge krav 7, hvor nævnte jernsupplement er elementært jern.
  9. 9. Navlestrengsblodet til anvendelse ifølge krav 2, hvor nævnte blodadditiv er røde blodlegemer ikke opnået fra navlestrengsblod. 35 £
  10. 10. Navlestrengsblodet til anvendelse ifølge krav 9, hvor nævnte røde blodlegemer er blevet bestrålet med mindst 2500 cGy af stråling, eller hvor nævnte røde blodlegemer er blevet leukodepleteret.
  11. 11. Navlestrengsblodet til anvendelse ifølge krav 1, hvor nævnte præmature spædbarn har gennemlevet fra 23 til 25 uger af svangerskab ved fødslen, fra 26 til 29 uger af svangerskab ved fødslen, fra 30 til 33 uger af svangerskab ved fødslen, eller fra 34 til 37 uger af svangerskab ved fødslen.
  12. 12. Navlestrengsblodet til anvendelse ifølge krav 1, hvor nævnte præmature spædbarn vejer 800 gram eller mere ved fødslen, 500 gram til 800 gram ved fødslen, eller mindre end 500 gram ved fødslen.
  13. 13. Navlestrengsblodet til anvendelse ifølge krav 1, hvor nævnte navlestrengsblod 15 er autologt til det præmature spædbarn.
    4. Navlestrengsblodet til anvendelse ifølge krav 1, hvor placentastamcellerne er autologe til det præmature spædbarn.
  14. 15. Navlestrengsblodet til anvendelse ifølge krav 1, hvor nævnte navlestrengsblod er opnået fra en efterfødsel-pattedyrsplacenta af en fuldbåren fødsel.
  15. 16. Navlestrengsblodet til anvendelse ifølge krav 1, hvor nævnte navlestrengsblod er opnået fra en efterfødsel-pattedyrsplacenta af en for tidlig fødsel. 25
  16. 17. Navlestrengsblodet til anvendelse ifølge krav 16, hvor nævnte placenta er placentaen af nævnte præmature spædbarn, placentaen af et spædbarn født ved 26 til 29 ugers svangerskab, placentaen af et spædbarn født ved 30 til 33 ugers svangerskab, eller placentaen af et spædbarn født ved 34 til 37 ugers 30 svangerskab.
  17. 18. Navlestrengsblodet til anvendelse ifølge krav 1, hvor nævnte navlestrengsblod er opnået fra en navlestrengsblodbank.
  18. 19. Navlestrengsblodet til anvendelse ifølge krav 1, hvor nævnte placentastamceller er stamceller isoleret fra placentaperfusat forud for nævnte anvendelse.
  19. 20. Navlestrengsblodet til anvendelse ifølge krav 1, hvor nævnte placentastamceller er stamceller indeholdt i placentaperfusat.
  20. 21. Navlestrengsblodet til anvendelse ifølge krav 1, hvor nævnte placentastamceller er opnået fra en efterfødsel-pattedyrsplacenta af en fuldbåren 10 fødsel, fra en efterfødsel-pattedyrsplacenta af en for tidlig fødsel, eller fra en placenta af nævnte præmature spædbarn.
  21. 22. Navlestrengsblodet til anvendelse ifølge krav 1, hvor nævnte placentastamceller er opnået fra en placenta af et spædbarn født ved 23 til 25 15 ugers svangerskab, fra en placenta af et spædbarn født ved 26 til 29 ugers svangerskab, fra en placenta af et spædbarn født ved 30 til 33 ugers svangerskab, eller fra en placenta af et spædbarn født ved 34 til 37 ugers svangerskab.
  22. 23. Navlestrengsblodet til anvendelse ifølge krav 1, hvor nævnte navlestrengsblod eller nævnte placentastamceller ikke er immunotypebestemt forud for nævnte anvendelse.
  23. 24. Navlestrengsblodet til anvendelse ifølge krav 1, hvor nævnte navlestrengsblod 25 er præpareret til at blive administreret én gang efter fødslen af det præmature spædbarn, en flerhed af gange efter fødslen af det præmature spædbarn, inden for én time efter fødslen af det præmature spædbarn, inden for 12 timer efter fødslen af det præmature spædbarn, inden for 24 timer efter fødslen af det præmature spædbarn, eller inden for én uge efter fødslen af det præmature 30 spædbarn.
  24. 25. Navlestrengsblodet til anvendelse ifølge krav 1, hvor nævnte navlestrengsblod omfatter 1 x 105 til 1 x 106 CD34+ celler per kilogram kropsvægt af nævnte præmature spædbarn. 35 Η-
  25. 26. Navlestrengsblodet til anvendelse ifølge krav 1, hvor nævnte placentastamceller og nævnte navlestrengsblod sammen omfatter 1 x 105 til 1 x 106 CD34+ celler per kilogram kropsvægt af nævnte præmature spædbarn.
  26. 27. Navlestrengsblodet til anvendelse ifølge krav 1, hvor nævnte navlestrengsblod er præpareret til at blive administreret ved intravenøs indsprøjtning.
  27. 28. Navlestrengsblodet til anvendelse ifølge krav 1, hvor nævnte navlestrengsblod er præpareret til at blive administreret inden for 1 time efter fødslen, inden for 12 10 timer efter fødslen, inden for 2 dage efter fødslen, eller inden for 2 uger efter fødslen.
DK08847846.6T 2007-11-07 2008-11-07 Anvendelse af navlestrengsblod i behandlingen af komplikationer i forbindelse med præterm fødsel DK2217329T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US237507P 2007-11-07 2007-11-07
PCT/US2008/012540 WO2009061447A2 (en) 2007-11-07 2008-11-07 Treatment of premature birth complications

Publications (1)

Publication Number Publication Date
DK2217329T3 true DK2217329T3 (da) 2018-04-23

Family

ID=40626389

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08847846.6T DK2217329T3 (da) 2007-11-07 2008-11-07 Anvendelse af navlestrengsblod i behandlingen af komplikationer i forbindelse med præterm fødsel

Country Status (16)

Country Link
US (4) US20090136471A1 (da)
EP (2) EP2217329B1 (da)
JP (6) JP2011503064A (da)
KR (8) KR20190004832A (da)
CN (2) CN101909694A (da)
AU (1) AU2008325142A1 (da)
CA (1) CA2704746A1 (da)
DK (1) DK2217329T3 (da)
ES (1) ES2667210T3 (da)
HK (2) HK1232146A1 (da)
IL (1) IL205595A0 (da)
MX (1) MX2010005018A (da)
NO (1) NO2217329T3 (da)
RU (1) RU2010123002A (da)
WO (1) WO2009061447A2 (da)
ZA (1) ZA201003057B (da)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7311905B2 (en) * 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
WO2002046373A1 (en) 2000-12-06 2002-06-13 Hariri Robert J Method of collecting placental stem cells
ES2558626T3 (es) * 2001-02-14 2016-02-05 Anthrogenesis Corporation Placenta post-parto de mamíferos, su uso y células madre placentarias de la misma
US7498171B2 (en) * 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
WO2004047770A2 (en) * 2002-11-26 2004-06-10 Anthrogenesis Corporation Cytotherapeutics, cytotherapeutic units and methods for treatments using them
CA2560725A1 (en) * 2004-03-26 2005-10-20 Celgene Corporation Systems and methods for providing a stem cell bank
NZ612132A (en) * 2005-10-13 2015-01-30 Anthrogenesis Corp Immunomodulation using placental stem cells
JP5203212B2 (ja) * 2005-10-13 2013-06-05 アントフロゲネシス コーポレーション 胎盤由来幹細胞からのオリゴデンドロサイトの産生
EP1976978A2 (en) * 2005-12-29 2008-10-08 Anthrogenesis Corporation Co-culture of placental stem cells and stem cells from a second source
CN108559725A (zh) 2005-12-29 2018-09-21 人类起源公司 胎盘干细胞群
KR20080097190A (ko) * 2005-12-29 2008-11-04 안트로제네시스 코포레이션 태반 줄기세포의 수집과 보존을 위한 개선된 조성물과 이조성물의 이용 방법
US7993918B2 (en) 2006-08-04 2011-08-09 Anthrogenesis Corporation Tumor suppression using placental stem cells
CN104099290A (zh) 2006-10-23 2014-10-15 人类起源公司 用胎盘细胞群治疗骨缺损的方法和组合物
EP3103462A1 (en) 2007-02-12 2016-12-14 Anthrogenesis Corporation Treatment of inflammatory diseases using placental stem cells
JP2010518812A (ja) * 2007-02-12 2010-06-03 アンスロジェネシス コーポレーション 接着性胎盤幹細胞由来の肝細胞および軟骨細胞、ならびにcd34+、cd45−胎盤幹細胞の濃縮細胞集団
US9200253B1 (en) 2007-08-06 2015-12-01 Anthrogenesis Corporation Method of producing erythrocytes
KR20190132556A (ko) 2007-09-28 2019-11-27 안트로제네시스 코포레이션 인간 태반 관류액 및 인간 태반-유래 중간체 천연 킬러 세포를 사용한 종양 억제 방법
DK2217329T3 (da) * 2007-11-07 2018-04-23 Anthrogenesis Corp Anvendelse af navlestrengsblod i behandlingen af komplikationer i forbindelse med præterm fødsel
MX339624B (es) 2008-08-20 2016-06-02 Anthrogenesis Corp Composiciones mejoradas de celulas y metodos para preparar las mismas.
AU2009283161A1 (en) 2008-08-22 2010-02-25 Anthrogenesis Corporation Methods and compositions for treatment of bone defects with placental cell populations
US9096827B2 (en) * 2008-09-02 2015-08-04 Pluristem Ltd. Adherent cells from placenta tissue and use thereof in therapy
JP5869342B2 (ja) 2008-11-19 2016-02-24 アンスロジェネシス コーポレーション 羊膜由来接着細胞
NZ619359A (en) 2009-07-02 2015-07-31 Anthrogenesis Corp Method of producing erythrocytes without feeder cells
CA2787992A1 (en) 2010-01-26 2011-08-04 Anthrogenesis Corporation Treatment of bone-related cancers using placental stem cells
TW201703777A (zh) 2010-04-07 2017-02-01 安瑟吉納西斯公司 利用胎盤幹細胞之血管新生
US8562973B2 (en) 2010-04-08 2013-10-22 Anthrogenesis Corporation Treatment of sarcoidosis using placental stem cells
US10130736B1 (en) 2010-05-14 2018-11-20 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US9352003B1 (en) 2010-05-14 2016-05-31 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US8883210B1 (en) 2010-05-14 2014-11-11 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
WO2012003960A1 (en) * 2010-07-06 2012-01-12 Augustinus Bader Topical application of erythropoietin for the treatment of eye disorders and injuries
MX342995B (es) 2010-07-13 2016-10-21 Anthrogenesis Corp Métodos de generar células asesinas naturales.
AU2011352036A1 (en) 2010-12-31 2013-07-18 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory RNA molecules
CN113559126A (zh) 2011-06-01 2021-10-29 人类起源公司 利用胎盘干细胞治疗疼痛
US10190092B2 (en) 2011-08-11 2019-01-29 Robert A. Dracker Procurement of placental stem cells
US9925221B2 (en) 2011-09-09 2018-03-27 Celularity, Inc. Treatment of amyotrophic lateral sclerosis using placental stem cells
US20130216502A1 (en) * 2012-02-22 2013-08-22 Nationwide Children's Hospital Inc. Methods of Treating Intestinal Injury Using Heparin Binding Epidermal Growth Factor and Stem Cells
KR101405620B1 (ko) * 2012-09-07 2014-06-10 사회복지법인 삼성생명공익재단 중간엽 줄기세포를 포함하는 미숙아 뇌실 내 출혈 치료용 조성물
US9763983B2 (en) 2013-02-05 2017-09-19 Anthrogenesis Corporation Natural killer cells from placenta
RU2676303C2 (ru) * 2013-07-11 2018-12-27 Новартис Аг Использование антагониста vegf для лечения ретролентальной фиброплазии
CN103756965B (zh) * 2014-01-27 2016-04-06 山东省齐鲁干细胞工程有限公司 一种从胎盘中灌洗造血干细胞的方法
WO2015164233A1 (en) * 2014-04-21 2015-10-29 Anthrogenesis Corporation Treatment of conditions and complications in infants
WO2016019332A1 (en) * 2014-07-29 2016-02-04 Ingeneron, Inc. Method and apparatus for recovery of umbilical cord tissue derived regenerative cells and uses thereof
US10584370B2 (en) 2014-12-16 2020-03-10 Soft Cell Biological Research, Llc Screening for L-form bacteria
CA3177726A1 (en) 2015-05-21 2016-11-24 Musculoskeletal Transplant Foundation Modified demineralized cortical bone fibers
RU2624253C1 (ru) * 2016-03-17 2017-07-03 Федеральное государственное бюджетное учреждение "Научный центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова" Министерства здравоохранения Российской Федерации Метод заготовки и применения аутологичных эритроцитов из пуповинной крови для коррекции анемии у новорожденных
US20180274005A1 (en) * 2017-03-24 2018-09-27 Soft Cell Biological Research, Llc Cord blood therapy to treat chronic disease caused by l-form bacteria
CN111514392A (zh) * 2020-04-29 2020-08-11 广州市天河诺亚生物工程有限公司 一种可用于预防早产儿并发症的自体脐带血处理方法及其应用
CN113332507A (zh) * 2021-06-11 2021-09-03 广东省妇幼保健院 一种脐带血采集方法及其应用
WO2023172960A1 (en) * 2022-03-09 2023-09-14 The Children's Hospital Of Philadelphia System and method of treatment for premature fetus

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3862002A (en) * 1962-05-08 1975-01-21 Sanfar Lab Inc Production of physiologically active placental substances
US4798824A (en) * 1985-10-03 1989-01-17 Wisconsin Alumni Research Foundation Perfusate for the preservation of organs
US5863531A (en) * 1986-04-18 1999-01-26 Advanced Tissue Sciences, Inc. In vitro preparation of tubular tissue structures by stromal cell culture on a three-dimensional framework
US4796605A (en) * 1986-07-11 1989-01-10 Atom Kabushiki Kaisha Incubator
US5004681B1 (en) 1987-11-12 2000-04-11 Biocyte Corp Preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood
US5192553A (en) * 1987-11-12 1993-03-09 Biocyte Corporation Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood and methods of therapeutic use
US5284766A (en) * 1989-02-10 1994-02-08 Kao Corporation Bed material for cell culture
US5272263A (en) * 1989-04-28 1993-12-21 Biogen, Inc. DNA sequences encoding vascular cell adhesion molecules (VCAMS)
US5605822A (en) * 1989-06-15 1997-02-25 The Regents Of The University Of Michigan Methods, compositions and devices for growing human hematopoietic cells
US5464764A (en) * 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5061620A (en) * 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5733542A (en) * 1990-11-16 1998-03-31 Haynesworth; Stephen E. Enhancing bone marrow engraftment using MSCS
US5486359A (en) * 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5197985A (en) * 1990-11-16 1993-03-30 Caplan Arnold I Method for enhancing the implantation and differentiation of marrow-derived mesenchymal cells
US6010696A (en) * 1990-11-16 2000-01-04 Osiris Therapeutics, Inc. Enhancing hematopoietic progenitor cell engraftment using mesenchymal stem cells
US5190556A (en) 1991-03-19 1993-03-02 O.B. Tech, Inc. Cord cutter sampler
US5356373A (en) * 1991-11-15 1994-10-18 Miles Inc. Method and apparatus for autologous transfusions in premature infants
DE69431473T2 (de) * 1993-03-31 2003-08-07 Pro-Neuron, Inc. Inhibitor der stammzellproliferation und seine verwendung
US5709854A (en) 1993-04-30 1998-01-20 Massachusetts Institute Of Technology Tissue formation by injecting a cell-polymeric solution that gels in vivo
US5698579A (en) * 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
US5372581A (en) 1993-07-21 1994-12-13 Minneapolis Children's Services Corporation Method and apparatus for placental blood collection
US5591625A (en) * 1993-11-24 1997-01-07 Case Western Reserve University Transduced mesenchymal stem cells
US6288030B1 (en) * 1993-12-22 2001-09-11 Amgen Inc. Stem cell factor formulations and methods
DE69531638T2 (de) * 1994-06-06 2004-06-17 Osiris Therapeutics, Inc. Biomatrix für geweberegenaration
US6174333B1 (en) * 1994-06-06 2001-01-16 Osiris Therapeutics, Inc. Biomatrix for soft tissue regeneration using mesenchymal stem cells
US6103522A (en) * 1994-07-20 2000-08-15 Fred Hutchinson Cancer Research Center Human marrow stromal cell lines which sustain hematopoiesis
US5516532A (en) 1994-08-05 1996-05-14 Children's Medical Center Corporation Injectable non-immunogenic cartilage and bone preparation
WO1996015230A2 (en) * 1994-11-16 1996-05-23 Amgen Inc. Use of stem cell factor and soluble interleukin-6 receptor for the ex vivo expansion of hematopoietic multipotential cells
US5874301A (en) * 1994-11-21 1999-02-23 National Jewish Center For Immunology And Respiratory Medicine Embryonic cell populations and methods to isolate such populations
US5728306A (en) 1994-12-23 1998-03-17 Baxter International Inc. Leukodepletion filter and method for filtering leukocytes from freshly drawn blood
US5695998A (en) * 1995-02-10 1997-12-09 Purdue Research Foundation Submucosa as a growth substrate for islet cells
US6011000A (en) * 1995-03-03 2000-01-04 Perrine; Susan P. Compositions for the treatment of blood disorders
US5716616A (en) * 1995-03-28 1998-02-10 Thomas Jefferson University Isolated stromal cells for treating diseases, disorders or conditions characterized by bone defects
US5733541A (en) * 1995-04-21 1998-03-31 The Regent Of The University Of Michigan Hematopoietic cells: compositions and methods
US5925567A (en) * 1995-05-19 1999-07-20 T. Breeders, Inc. Selective expansion of target cell populations
US5830708A (en) 1995-06-06 1998-11-03 Advanced Tissue Sciences, Inc. Methods for production of a naturally secreted extracellular matrix
US5877299A (en) * 1995-06-16 1999-03-02 Stemcell Technologies Inc. Methods for preparing enriched human hematopoietic cell preparations
US5654381A (en) 1995-06-16 1997-08-05 Massachusetts Institute Of Technology Functionalized polyester graft copolymers
US5858782A (en) * 1995-11-13 1999-01-12 Regents Of The University Of Michigan Functional human hematopoietic cells
US6337387B1 (en) * 1995-11-17 2002-01-08 Asahi Kasei Kabushiki Kaisha Differentiation-suppressive polypeptide
US5716794A (en) * 1996-03-29 1998-02-10 Xybernaut Corporation Celiac antigen
EP2105138A3 (en) * 1996-04-19 2013-06-05 Osiris Therapeutics, Inc. Regeneration and augmentation of bone using mesenchymal stem cells
US5919176A (en) * 1996-05-14 1999-07-06 Children's Hospital Medical Center Of Northern California Apparatus and method for collecting blood from an umbilical cord
US6281230B1 (en) * 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
US5827740A (en) * 1996-07-30 1998-10-27 Osiris Therapeutics, Inc. Adipogenic differentiation of human mesenchymal stem cells
US6358737B1 (en) * 1996-07-31 2002-03-19 Board Of Regents, The University Of Texas System Osteocyte cell lines
US5916202A (en) * 1996-08-30 1999-06-29 Haswell; John N. Umbilical cord blood collection
US6335195B1 (en) * 1997-01-28 2002-01-01 Maret Corporation Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation
US5879318A (en) * 1997-08-18 1999-03-09 Npbi International B.V. Method of and closed system for collecting and processing umbilical cord blood
AU9127098A (en) * 1997-09-04 1999-03-22 Osiris Therapeutics, Inc. Ligands that modulate differentiation of mesenchymal stem cells
US5874448A (en) * 1997-11-18 1999-02-23 Celgene Corporation Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels
EP1062321B1 (en) * 1998-03-13 2004-12-29 Osiris Therapeutics, Inc. Uses for humane non-autologous mesenchymal stem cells
US6030836A (en) * 1998-06-08 2000-02-29 Osiris Therapeutics, Inc. Vitro maintenance of hematopoietic stem cells
US6184035B1 (en) * 1998-11-18 2001-02-06 California Institute Of Technology Methods for isolation and activation of, and control of differentiation from, skeletal muscle stem or progenitor cells
US6102871A (en) 1998-11-23 2000-08-15 Coe; Rosemarie O. Blood collection funnel
US20030007954A1 (en) * 1999-04-12 2003-01-09 Gail K. Naughton Methods for using a three-dimensional stromal tissue to promote angiogenesis
AU4860900A (en) 1999-06-02 2000-12-18 Lifebank Services, L.L.C. Methods of isolation, cryopreservation, and therapeutic use of human amniotic epithelial cells
US6333029B1 (en) * 1999-06-30 2001-12-25 Ethicon, Inc. Porous tissue scaffoldings for the repair of regeneration of tissue
US8075881B2 (en) * 1999-08-05 2011-12-13 Regents Of The University Of Minnesota Use of multipotent adult stem cells in treatment of myocardial infarction and congestive heart failure
US6685936B2 (en) * 1999-10-12 2004-02-03 Osiris Therapeutics, Inc. Suppressor cells induced by culture with mesenchymal stem cells for treatment of immune responses in transplantation
EP1263428A2 (en) * 2000-01-18 2002-12-11 Buhimschi, Irina Free radical scavengers for the treatment of premature birth
JP2004500824A (ja) * 2000-03-09 2004-01-15 クリオ−セル インターナショナル インコーポレーティッド 脳および脊髄の修復のための神経組織源としてのヒト臍帯血
US7282366B2 (en) * 2000-04-27 2007-10-16 Geron Corporation Hepatocytes for therapy and drug screening made from embryonic stem cells
US20050009876A1 (en) * 2000-07-31 2005-01-13 Bhagwat Shripad S. Indazole compounds, compositions thereof and methods of treatment therewith
EP1402266B1 (en) * 2000-11-28 2011-01-12 Premacure AB Reducing RISK OF COMPLICATIONS OF PREMATURITY
US6818216B2 (en) * 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies
WO2002046373A1 (en) * 2000-12-06 2002-06-13 Hariri Robert J Method of collecting placental stem cells
US7311905B2 (en) * 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
US20030045552A1 (en) * 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
EP2316919B1 (en) * 2001-02-14 2015-10-07 Anthrogenesis Corporation Post-partum mammalian placenta, its use and placental stem cells therefrom
ES2558626T3 (es) * 2001-02-14 2016-02-05 Anthrogenesis Corporation Placenta post-parto de mamíferos, su uso y células madre placentarias de la misma
US20030044977A1 (en) * 2001-08-10 2003-03-06 Norio Sakuragawa Human stem cells originated from human amniotic mesenchymal cell layer
WO2003061591A2 (en) * 2002-01-22 2003-07-31 Advanced Cell Technology, Inc. Stem cell-derived endothelial cells modified to disrupt tumor angiogenesis
NZ534643A (en) * 2002-02-13 2010-06-25 Anthrogenesis Corp Embryonic-like stem cells derived from post-partum mammalian placenta and uses and methods of treatment using said cells
US20030187515A1 (en) * 2002-03-26 2003-10-02 Hariri Robert J. Collagen biofabric and methods of preparing and using the collagen biofabric
US7498171B2 (en) 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
CN1668733A (zh) * 2002-05-30 2005-09-14 细胞基因公司 利用jnk或mkk抑制剂调节细胞分化并治疗骨髓增生异常和脊髓发育不良综合症的方法
US7422736B2 (en) * 2002-07-26 2008-09-09 Food Industry Research And Development Institute Somatic pluripotent cells
NZ542127A (en) * 2003-02-13 2008-04-30 Anthrogenesis Corp Use of umbilical cord blood to treat individuals having a disease, disorder or condition
EP1641913B1 (en) * 2003-06-27 2016-01-06 DePuy Synthes Products, Inc. Postpartum cells derived from umbilical cord tissue, and methods of making and using the same
US20050042595A1 (en) * 2003-08-14 2005-02-24 Martin Haas Banking of multipotent amniotic fetal stem cells
EP2065383A1 (en) * 2003-11-19 2009-06-03 Signal Pharmaceuticals, Inc. Indazole compounds and methods of use thereof as protein kinase inhibitors
US7909806B2 (en) * 2004-09-23 2011-03-22 Anthrogenesis Corporation Cord blood and placenta collection kit
US7147626B2 (en) 2004-09-23 2006-12-12 Celgene Corporation Cord blood and placenta collection kit
CA2593549C (en) * 2005-01-07 2016-04-26 Wake Forest University Health Sciences Regeneration of pancreatic islets by amniotic fluid stem cell therapy
US20060236456A1 (en) * 2005-03-03 2006-10-26 Beale Robert S Patient transport method and apparatus
KR20080031735A (ko) * 2005-06-10 2008-04-10 셀진 코포레이션 인간 태반 콜라겐 조성물, 그의 제조 방법, 그의 사용 방법및 상기 조성물을 포함하는 키트
JP2008544818A (ja) * 2005-06-30 2008-12-11 アントフロゲネシス コーポレーション 胎盤由来コラーゲンバイオ線維を用いた鼓膜の修復
US20070021762A1 (en) * 2005-07-13 2007-01-25 Qing Liu Ocular plug formed from placenta derived collagen biofabric
US7928280B2 (en) * 2005-07-13 2011-04-19 Anthrogenesis Corporation Treatment of leg ulcers using placenta derived collagen biofabric
WO2007011693A2 (en) * 2005-07-14 2007-01-25 Medistem Laboratories, Inc. Compositions of placentally-derived stem cells for the treatment of cancer
JP5203212B2 (ja) * 2005-10-13 2013-06-05 アントフロゲネシス コーポレーション 胎盤由来幹細胞からのオリゴデンドロサイトの産生
NZ612132A (en) * 2005-10-13 2015-01-30 Anthrogenesis Corp Immunomodulation using placental stem cells
KR100697326B1 (ko) * 2005-12-02 2007-03-20 재단법인서울대학교산학협력재단 Oct4 발현능을 가지는 제대혈 유래 다분화능 성체줄기세포 및 그의 제조방법
SG170789A1 (en) * 2005-12-28 2011-05-30 Ethicon Inc Treatment of peripheral vascular disease using postpartum-derived cells
CN108559725A (zh) * 2005-12-29 2018-09-21 人类起源公司 胎盘干细胞群
WO2007100560A2 (en) * 2006-02-28 2007-09-07 Bristol-Myers Squibb Company Use of dha and ara in the preparation of a composition for inducing the expression of pulmonary surfactant protein-b
WO2007124594A1 (en) * 2006-04-27 2007-11-08 Cell Therapy Technologies, Inc. Et Al. Stem cells for treating lung diseases
AU2007258514A1 (en) * 2006-06-09 2007-12-21 Anthrogenesis Corporation Placental niche and use thereof to culture stem cells
WO2008021391A1 (en) * 2006-08-15 2008-02-21 Anthrogenesis Corporation Umbilical cord biomaterial for medical use
DK2217329T3 (da) * 2007-11-07 2018-04-23 Anthrogenesis Corp Anvendelse af navlestrengsblod i behandlingen af komplikationer i forbindelse med præterm fødsel
MX339624B (es) * 2008-08-20 2016-06-02 Anthrogenesis Corp Composiciones mejoradas de celulas y metodos para preparar las mismas.
NZ591294A (en) * 2008-08-20 2012-10-26 Anthrogenesis Corp Treatment of stroke using isolated placental cells
AU2009283161A1 (en) * 2008-08-22 2010-02-25 Anthrogenesis Corporation Methods and compositions for treatment of bone defects with placental cell populations
US9168273B2 (en) * 2009-03-05 2015-10-27 Robert A. Dracker Intrathecal administration of autologous stem cells to treat intraventricular hemorrhage in premature infants
US20110294879A1 (en) * 2010-05-28 2011-12-01 Xenoport, Inc. Method of treatment of fragile x syndrome, down's syndrome, autism and related disorders

Also Published As

Publication number Publication date
US20130259845A1 (en) 2013-10-03
KR20100100855A (ko) 2010-09-15
WO2009061447A2 (en) 2009-05-14
MX2010005018A (es) 2010-05-27
NO2217329T3 (da) 2018-06-09
KR20160040739A (ko) 2016-04-14
KR20170116221A (ko) 2017-10-18
WO2009061447A9 (en) 2009-09-03
US20230090316A1 (en) 2023-03-23
KR20200028045A (ko) 2020-03-13
IL205595A0 (en) 2010-11-30
JP2015120713A (ja) 2015-07-02
CN101909694A (zh) 2010-12-08
EP3345609A1 (en) 2018-07-11
US20190321413A1 (en) 2019-10-24
ZA201003057B (en) 2011-07-27
JP2022070952A (ja) 2022-05-13
HK1232146A1 (zh) 2018-01-05
US20090136471A1 (en) 2009-05-28
KR20220098055A (ko) 2022-07-08
JP2016216470A (ja) 2016-12-22
AU2008325142A1 (en) 2009-05-14
WO2009061447A3 (en) 2010-01-21
CA2704746A1 (en) 2009-05-14
EP2217329A2 (en) 2010-08-18
KR20190004832A (ko) 2019-01-14
EP2217329B1 (en) 2018-01-10
KR20210056449A (ko) 2021-05-18
ES2667210T3 (es) 2018-05-10
HK1257536A1 (zh) 2019-10-25
JP2011503064A (ja) 2011-01-27
KR20230035451A (ko) 2023-03-13
RU2010123002A (ru) 2011-12-20
JP2018052944A (ja) 2018-04-05
JP2019218366A (ja) 2019-12-26
CN106214702A (zh) 2016-12-14

Similar Documents

Publication Publication Date Title
US20230090316A1 (en) Treatment of premature birth complications
US8057789B2 (en) Placental stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
NZ534643A (en) Embryonic-like stem cells derived from post-partum mammalian placenta and uses and methods of treatment using said cells
IL156303A (en) A method of collecting placental stem cells from a human placenta after birth
JP2023078156A (ja) ヒト胎盤および造血細胞由来の細胞による治療
US20170042944A1 (en) Treatment of conditions and complications in infants
ES2703784T3 (es) Uso de células madre placentarias en el tratamiento de la lesión renal aguda
US20230210909A1 (en) Placenta-derived adherent (pda) stem cell for the treatment of adults with sars-cov-2 related acute respiratory failure and ards (covid-19)
EP2301343A1 (en) Embryonic-like stem cells derived from post-partum mammalian placenta and uses and methods of treatment using said cells
US20170224739A1 (en) Placental stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells